Wegovy maker Novo Nordisk's sales hike in second quarter

Sales of its blockbuster Wegovy obesity drug rose 67% over the period to 19.53 billion Danish kroner, slightly below the 20 billion Danish kroner analysts had forecast. Quarterly net profit came in at 26.5 billion Danish kroner, versus 26.6 billion Danish kroner analysts expected. Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Sales of Novo Nordisk's blockbuster Wegovy weight loss drug surged in the second quarter, the company said in its latest report, days after ...